Literature DB >> 1593901

Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia.

L M Secker-Walker1, R Berger, P Fenaux, J L Lai, B Nelken, M Garson, P M Michael, A Hagemeijer, C J Harrison, Y Kaneko.   

Abstract

The recurring chromosomal 1;19 translocation in acute lymphoblastic leukemia (ALL) occurs in balanced t(1;19) (q23;p13) and unbalanced, -19, +der(19)t(1;19)(q23;p13) forms. The clinical features and outcome were compared for 30 patients with the t(1;19) and 36 patients with the der(19) forms. These were 45 children (less than 1-14 years) and 21 adults (15-54 years) (median age 9.0 years), 41 females, 25 males, with median white blood count (WBC) 20.9 x 10(9)/1. Patients were classified by karyotype thus: t(1;19) 11 cases; t(1;19) with additional change (+A) 19 cases; der(19) 17 cases; and der(19) +A, 19 cases. Non-random additional structural abnormalities included involvement of 1q, 6q, i(7q), i(9q), 9p, and 13q. The only significant difference in clinical or blast cell features between patients with the t(1;19) and the der(19) was the greater age of adults with t(1;19) (p less than 0.05). Projected median event-free survival and survival of all cases together was 22 months and greater than 112 months respectively. Neither age nor WBC contributed significantly to prognosis. For patients at all ages, prognosis of der(19) was better than t(1;19). This was statistically significant for event-free and overall survival in childhood (p = 0.02 and p = 0.01 respectively) and was independent of age (p = 0.04 and p = 0.008 respectively) and WBC (p = 0.03 and p = 0.04 respectively). Future studies should examine separately the outcome for patients with the balanced and unbalanced forms of the t(1;19).

Entities:  

Mesh:

Year:  1992        PMID: 1593901

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Incidence and Prognostic Impact of TCF3-PBX1 Fusion in Childhood Acute Lymphoblastic Leukemia: A Single Centre Experience.

Authors:  Payal Malhotra; Sandeep Jain; Arushi Agarwal; Anurag Sharma; Narender Agarwal; Gauri Kapoor
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-22       Impact factor: 0.900

2.  Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.

Authors:  Ravin Garg; Hagop Kantarjian; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Denise Lovshe; Sherry Pierce; Susan O'Brien
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

3.  Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1.

Authors:  S Jeha; D Pei; S C Raimondi; M Onciu; D Campana; C Cheng; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Howard; J R Downing; W E Evans; M V Relling; C-H Pui
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 11.528

4.  Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.

Authors:  Thomas Burmeister; Nicola Gökbuget; Stefan Schwartz; Lars Fischer; Daniela Hubert; Annette Sindram; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

5.  Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report.

Authors:  Abdulsamad Wafa; Manar As'sad; Thomas Liehr; Abdulmunim Aljapawe; Walid Al Achkar
Journal:  J Med Case Rep       Date:  2017-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.